title: Maximally tolerated versus minimally effective dose: the case of rituximab in multiple sclerosis.
authors.forename: A Scott
authors.initials: AS
authors.lastname: Nielsen
authors.forename: Augusto
authors.initials: A
authors.lastname: Miravalle
authors.forename: Annette
authors.initials: A
authors.lastname: Langer-Gould
authors.forename: Joanna
authors.initials: J
authors.lastname: Cooper
authors.forename: Keith R
authors.initials: KR
authors.lastname: Edwards
authors.forename: R Philip
authors.initials: RP
authors.lastname: Kinkel
mesh_terms: D058846:Antibodies, Monoclonal, Murine-Derived / Q000008:administration & dosage* / Q000627:therapeutic use; D001402:B-Lymphocytes / Q000187:drug effects / Q000378:metabolism; D006801:Humans; D007155:Immunologic Factors / Q000008:administration & dosage / Q000627:therapeutic use; D020714:Maximum Tolerated Dose; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000188:drug therapy*; D000069283:Rituximab; D016896:Treatment Outcome
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D007155:Immunologic Factors; D000069283:Rituximab